Loading...
Loading...
EVAX| Name | Value |
|---|---|
| Revenues | 73.6K |
| Cost of Revenue | 0.0K |
| Gross Profit | 73.6K |
| Operating Expense | 4,473.3K |
| Operating I/L | -4,399.7K |
| Other Income/Expense | -338.8K |
| Interest Income | 541.3K |
| Pretax | -4,738.5K |
| Income Tax Expense | -178.4K |
| Net Income/Loss | -4,560.0K |
Evaxion Biotech A/S is a clinical-stage biotech company specializing in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company's product pipeline includes EVX-01, a cancer immunotherapy in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for various cancers. Additionally, the company is developing vaccines, EVX-B1, EVX-B2, and EVX-V1, in the pre-clinical stage for the treatment of bacterial and viral diseases.
